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PrasugrelIntroduction: Few studies have examined the relationship between the pharmacodynamics of antiplatelet drugs
and the risk of clinically signiﬁcant bleeding following percutaneous coronary intervention (PCI) for treating
acute coronary syndrome (ACS). We examined the associations between the pharmacodynamics of prasugrel
and clopidogrel and the incidence of bleeding events in the acute and chronic phases after PCI.
Materials and methods: We performed a post hoc analysis of the PRASFIT-ACS (PRASugrel compared with
clopidogrel For Japanese patIenTs with ACS undergoing PCI) study of patients in whom platelet reactivity was
determined as P2Y12 reaction units (PRU; VerifyNow® P2Y12 assay) or vasodilator-stimulated phosphoprotein-
phosphorylation reactivity index (VASP-PRI). Japanese patients were randomized to prasugrel (loading/
maintenance dose: 20/3.75 mg) or clopidogrel (300/75 mg), both in combination with aspirin, for 24–48
weeks. The bleeding outcome was a composite of major, minor, and clinically relevant bleeding.
Results:Overall, 66/685 (9.6%) and 65/678 (9.6%) of prasugrel- and clopidogrel-treated patients, respectively, ex-
periencedmajor, minor, or clinically relevant bleeding. PRU and VASP-PRI at 5–12 h or in steady state conditions
(at 4 weeks) were not associated with the risk of bleeding in the acute (to day 3) or chronic (from day 4 to
14 days after treatment discontinuation) phases of treatment, respectively. Less than 9% of patients with low
on-treatment platelet reactivity (deﬁned as PRU b 85 or VASP-PRI b 16) experienced bleeding events.
Conclusion:No direct association of the pharmacodynamics of prasugrel and clopidogrelwith the risk of bleeding
was observed in this cohort of Japanese ACS patients following PCI.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Patients undergoing elective or emergent percutaneous coronary in-
tervention (PCI) are routinely prescribed antiplatelet drugs, including
aspirin and thienopyridines (e.g., prasugrel and clopidogrel), to reduce
the risk of stent thrombosis and major adverse cardiovascular events
(MACE).
Although clopidogrel is one of the most widely used drugs in
this setting, TRITON-TIMI 38 (Trial to Assess Improvement in Therapeu-
tic Outcomes by Optimizing Platelet Inhibition With Prasugrel-
Thrombolysis In Myocardial Infarction 38) [1] showed that prasugrel
was associatedwith a lower incidence of ischemic events, but a higher in-
cidence of bleeding events than clopidogrel. Similar efﬁcacy results were
obtained in the Japanese PRASFIT-ACS (PRASugrel compared with
clopidogrel For Japanese patIenTs with Acute Coronary Syndrome [ACS]
undergoing PCI) study [2]. In that study, the hazard ratio (HR) for the in-
cidence of MACE in the prasugrel group relative to the clopidogrel group
over 24 weeks of treatment was 0.77 (95% conﬁdence interval [CI]
0.56–1.07), corresponding to a risk reduction of 23%.
In TRITON-TIMI 38 [1], prasugrel (loading dose [LD]: 60mg;mainte-
nance dose [MD]: 10 mg) was associated with a higher incidence of
non-coronary artery bypass graft (CABG)-related TIMI major or minor
bleeding events than clopidogrel (HR 1.31, 95% CI 1.11–1.56), However,
in PRASFIT-ACS, the incidence of major or minor bleeding events was
5.7% (39/685) in the prasugrel group (LD: 20 mg; MD: 3.75 mg) and
4.3% (29/678) in the clopidogrel group (HR 1.30, 95% CI 0.81–2.11),
and the incidences of non-CABG-relatedmajor, minor, or clinically rele-
vant bleeding were similar in both groups (HR 0.98, 95% CI 0.70–1.38).
The results of the TRITON-TIMI 38 and PRASFIT-ACS studies, as well
as other clinical trials and clinical experience, are indicative of a thera-
peutic window for antiplatelet drugs, in which the prescribed drug
must achieve sufﬁcient platelet inhibition to prevent MACE, but avoid
excessive platelet inhibition that might increase the risk of bleeding
events.
In clinical practice, the risk of thrombotic events is increased in
patients with high on-treatment platelet reactivity, indicative of a low
response to antiplatelet drugs [3–6], but the risk of bleeding is increased
in patientswith lowon-treatment platelet reactivity, indicative of a high
response to antiplatelet drugs [6–8]. To date, however, few studies have
examined the relationship between the pharmacodynamics of anti-
platelet drugs and the risk of clinically signiﬁcant bleeding following
PCI to treat ACS.Fig. 1. Kaplan–Meier plot of the cumulative incidence of bleeding events (major bleeding, mino
period (from the start of study drug administration to 14 days after the completion of treatmeRetrospective analyses of the results of the PRASFIT-ACS study
showed that the incidence of thrombotic events was increased in pa-
tients with a P2Y12 reaction unit (PRU) of ≥262 at 5–12 h after PCI [9],
representing one end of the therapeutic window. To optimize prasugrel
therapy, clinicians should also be aware of the other end of the thera-
peutic window so that increasing the risk of bleeding can be avoided.
Therefore, the aim of the present analyses was to elucidate the rela-
tionship between platelet reactivity (i.e., PRU) and bleeding events in
the PRASFIT-ACS study to determine the optimal therapeutic window
for dual antiplatelet therapy in Japanese ACS patients undergoing PCI.
We ﬁrst examined the relationship between platelet reactivity at
5–12 h after starting treatment (i.e., acute phase of treatment) and bleed-
ing events occurring from Day 4 onwards. We then examined whether
the extent of platelet inhibition at steady state levels (4–5 days) is associ-
atedwith bleeding events occurring fromWeek 4 onwards in the chronic
phase of treatment.
2. Materials and methods
The design of the PRASFIT-ACS study is described in more detail in
our prior report [2] and the patients included in the present analyses
are the same as those included in an earlier post hoc analysis [9]. The
trial was registered with Japan Pharmaceutical Information Center
(identiﬁer: JapicCTI-101339).
The PRASFIT-ACS study enrolled Japanese ACS patients aged
≥20 years who were scheduled for coronary artery stenting if they
had symptoms lasting ≥10 min within 72 h before randomization,
ST-segment deviation ≥1 mm or T-wave inversion ≥3 mm, or elevated
cardiac biomarkers associated with necrosis.
Eligible patients were randomized in a 1:1 ratio to receive either
prasugrel (LD: 20 mg; MD: 3.75 mg) or clopidogrel (LD: 300 mg; MD:
75 mg). The LD was administered before PCI or up to 1 h after leaving
the cardiac catheter laboratory in urgent cases. TheMDwas administered
once daily after breakfast. All patients received aspirin (81–330mg for the
ﬁrst dose and 81–100 mg thereafter). Treatments were continued for
24–48 weeks depending on the stent type and recommended duration
of thienopyridine administration stated in the package inserts for the
stents. This duration of dual antiplatelet therapy was necessary because
bare metal stents were used to treat ACS in many patients.
The primary efﬁcacy outcome was the incidence of MACE, which
wasdeﬁned as a composite of cardiovascular death, nonfatalmyocardial
infarction, and nonfatal ischemic stroke. Safety outcomes included non-r bleeding, and clinically relevant bleeding combined) in all patients throughout the study
nt or discontinuation). Vertical lines indicate censored events.
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until 2 weeks after the last dose.
The following types of bleeding events were assessed: non-CABG-
related TIMImajor bleeding (e.g., intracranial bleeding or bleeding lead-
ing to a decrease in hemoglobin of ≥5 g/dl), non-CABG-related TIMI
minor bleeding (e.g., bleeding leading to a decrease in hemoglobin of
3– b 5 g/dl), clinically relevant non-major or minor bleeding from critical
sites (e.g., bleeding leading to a decrease in hemoglobin of b3 g/dl), other
types of bleeding not satisfying these criteria, and life-threatening bleed-
ing [10].
The pharmacodynamics of prasugrel and clopidogrel were assessed
in terms of platelet reactivity using the VerifyNow® P2Y12 assay
(Accumetrics, San Diego, CA, USA) to determine PRU and the
vasodilator-stimulated phosphoprotein (VASP) assay to determine the
phosphorylation reactivity index (PRI). PRU was determined as
described in our prior report [9]. VASP-PRI was measured using aFig. 2.Distribution of P2Y12 reactive units (PRU) and types of bleeding events according to the P
treatment. (B) PRU at 4 weeks after the loading dose and bleeding events from 4 days after stastandardized ﬂow cytometric assay as previously described [11]. Brieﬂy,
the PRI is the difference in VASP ﬂuorescence intensity between rest-
ing (+prostaglandin E1 [PGE1]) and activated (+ADP) platelets, and is
calculated from the median ﬂuorescence intensity (MFI) of samples in-
cubatedwith PGE1 alone or PGE1 and ADP using the following formula:
PRI = {[MFI(PGE1)−MFI(PGE1 + ADP)]/MFI(PGE1)} × 100.
Both assays were to be performedwherever feasible in patients who
permitted sample collection. Assays were performed at baseline, in the
LD phase (2–4, and 5–12 h after the LD), and during theMD phase (at 4,
12, 24, 36, and 48weeks after PCI). The assays were not mandatory and
were not possible in all patients because of difﬁculties in sample collec-
tion and processing.
Of 1363 patients enrolled in the PRASFIT-ACS study, the current
analyses focused on four subsets of patients: Subset 1—660 patients
with PRU data at 5–12 h (prasugrel, 328; clopidogrel, 332; Table S1);
Subset 2—1063 patients with PRU data at 4 weeks (prasugrel, 536;RU. (A) PRU at 5–12 h after the loading dose and bleeding events up to 3 days after starting
rting treatment with prasugrel or clopidogrel to 14 days after treatment discontinuation.
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at 5–12 h (prasugrel 463, clopidogrel, 471; Table S3); Subset 4—1083
patients with VASP-PRI data at 4 weeks (prasugrel, 548; clopidogrel,
535; Table S4). The four subsets differed in terms of the numbers of pa-
tients with evaluable PRU or VASP-PRI data at the speciﬁed time-points.
The analyses were conducted independently in all four subsets without
correction for multiplicity of statistical analyses or the dependencies
among each subset.
The Kaplan–Meiermethodwas used to plot the cumulative incidence
of bleeding events (combination of major bleeding, minor bleeding, and
clinically relevant bleeding) in all patients from the start of administra-
tion to 14 days after completion of treatment or discontinuation. The as-
sociation between PRU and bleeding events was examined by plotting
the distribution of bleeding events according to PRU.Multivariate Cox re-
gression analysis was used to compute adjusted HRs with corresponding
95% CIs for exhibiting bleeding events compared with not exhibiting
bleeding events, adjusting for variables (sex, body weight, age, eGFR,
complications, disease type, and treatment). Statistical analyses were
performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) and
Microsoft Excel 2010.Fig. 3.Distribution of bleeding events up to 3 days after starting treatmentwith prasugrel or clop
phoprotein-phosphorylation reactivity index (B) at 5–12h after starting treatment. Bleeding eve
represent the number of evaluable patients. The values in parentheses represent the numbers3. Results
Although the numbers of patients included in each of the four subsets
differed, the general characteristics of all four subsets were comparable
(Tables S1–S4). Of 685 and 678 patients in the prasugrel and clopidogrel
groups [2], respectively, 341 (49.8%) and 247 (36.4%) patients experi-
enced bleeding events; 66 (9.6%) and 65 (9.6%) patients experienced
major/minor/clinically relevant bleeding, 4 (0.6%) and 7 (1.0%) patients
had life-threatening bleeding, and 2 (0.3%) and 1 (0.1%) patients had
fatal bleeding. Fig. 1 shows a Kaplan–Meier plot of the incidence of
bleeding events (number at risk and % probability of major bleeding,
minor bleeding, and clinically relevant bleeding combined) in all pa-
tients throughout the study period. Fig. 2 shows the distribution of
PRU at either 5–12 h (Fig. 2A) or 4 weeks (Fig. 2B) after the loading
dose. Fig. 2 also shows the types of bleeding events (major, minor, or
clinically relevant) according to the PRU of the affected patient. Major
bleeding, minor bleeding, and clinically relevant bleeding occurred
in 1, 1, and 9 patients, respectively, in the prasugrel group and in 2, 4,
and 16 patients, respectively, in the clopidogrel group between Day 4
and Week 4.idogrel according to quartiles of P2Y12 reactivity units (A) or vasodilator-stimulated phos-
ntswere deﬁned asmajor,minor, or clinically signiﬁcant events. The values aboveeachbar
of patients with a bleeding event.
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acute phase
Because the risk of bleeding is highest in the acute period after the
LD through to the start of the MD of the antiplatelet drug (Fig. 1), we
ﬁrst examined whether the extent of platelet inhibition was associated
with the risk of bleeding events in the acute phase of treatment. To
achieve this, we plotted the distributions of major, minor, or clinically
relevant events occurring up to 3 days after starting according to quar-
tiles of PRU or VASP-PRI at 5–12 h. However, the incidence of bleeding
events was not increased in patients with low PRU or low VASP-PRI
(Fig. 3).
3.2. Relationship between platelet reactivity and bleeding events in the
chronic phase
We next examined whether the extent of platelet inhibition at
steady state levels was associated with the risk of bleeding in the chronic
phase of treatment. In this analysis, we used pharmacodynamic data at
Week 4 of treatment and evaluated bleeding events occurring betweenFig. 4.Distribution of bleeding events from4days after starting treatmentwith prasugrel or clop
units (A) or vasodilator-stimulated phosphoprotein-phosphorylation reactivity index (B) at 4 w
signiﬁcant events. The values above each bar represent the number of evaluable patients. TheDay 4 of treatment and 14 days after treatment discontinuation. When
we plotted the distribution of major, minor, or clinically relevant events
according to quartiles of PRU or VASP-PRI at 4 weeks (Fig. 4), the inci-
dence of bleeding events was not increased in patients with low PRU or
low VASP-PRI.3.3. Evaluation of low PRU and VASP-PRI values
Finally, we examined the putative relationship between platelet in-
hibition and bleeding events in patients with low PRU or VASP-PRI
values using cutoff values proposed by the Working Group on On-
Treatment Platelet Reactivity (PRU b 85; VASP-PRI b 16) [12]. Table 1
shows the incidence of bleeding events in patients with low PRU
(b85) or VASP-PRI (b16) values at 5–12 h or 4 weeks. Although the
incidence (95% conﬁdence interval) of bleeding events occurringwithin
3 days of starting treatment tended to be higher in patients with
PRU ≥85 than in patients with PRU b85 at 5–12 h (3.6% [2.2%–5.5%]
vs. 0% [0.0%–0.0%]; P = 0.0506), this difference was not observed in
other subsets of patients.idogrel to 14 days after treatment discontinuation according to quartiles of P2Y12 reactivity
eeks after starting treatment. Bleeding events were deﬁned as major, minor, or clinically
values in parentheses represent the numbers of patients with a bleeding event.
Table 1
Incidence of bleeding events according to platelet reactivity.
Period/test Cutoff
value
Patient
group
No. of
patients
with
bleeding
eventsa/no.
of evaluable
patients
Incidence
(%)
95% CI P-valueb
Bleeding events up to day 3
PRUc b85 All patients 0/104 0.0 (0.0–0.0) 0.0506
Prasugrel 0/102
Clopidogrel 0/2
≥85 All patients 20/556 3.6 (2.2–5.5)
Prasugrel 9/226
Clopidogrel 11/330
VASP-PRIc b16 All patients 2/94 2.1 (0.3–7.5) 0.6454
Prasugrel 2/91
Clopidogrel 0/3
≥16 All patients 25/840 3.0 (1.9–4.4)
Prasugrel 11/372
Clopidogrel 14/468
Bleeding events from day 4 to 48 weeks
PRUd b85 All patients 4/72 5.6 (1.5–13.6) 0.7296
Prasugrel 1/52
Clopidogrel 3/20
≥85 All patients 68/991 6.9 (5.4–8.6)
Prasugrel 32/484
Clopidogrel 36/507
VASP-PRId b16 All patients 6/73 8.2 (3.1–17.0) 0.6045
Prasugrel 3/50
Clopidogrel 3/23
≥16 All patients 68/1010 6.7 (5.3–8.5)
Prasugrel 31/498
Clopidogrel 37/512
CI, conﬁdence interval; PRU, P2Y12 reaction units; VASP-PRI, vasodilator-stimulated
phosphoprotein-phosphorylation reactivity index.
a Major, minor, or clinically relevant bleeding events.
b Generalized Wilcoxon test (for the comparisons PRU b85 vs. ≥85 and VASP-PRI b16
vs. ≥16 in all patients).
c Measured at 5–12 h after the loading dose.
d Measured at week 4 (corresponding to steady state pharmacodynamics of prasugrel
and clopidogrel).
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The results of a multivariate analysis to assess the associations of
background factors with TIMI major bleeding, TIMI minor bleeding,
and clinically relevant non-major or minor bleeding events throughoutTable 2
Hazard ratios and 95% conﬁdence intervals from univariate andmultivariate analyses of the asso
clinically relevant non-major or minor bleeding events throughout the study period.
Factor Univariate an
HR (95% CI)
Sex (female vs male) 2.480 (1.741–
Body weight (≤50 kg vs N50 kg) 2.836 (1.903–
Age (≥75 years vs b75 years) 2.195 (1.541–
eGFR
Moderate or greater decreasea (vs normal or mild) 1.641 (1.112–
Unknown (vs normal or mild) 0.933 (0.469–
Hypertension (yes vs no) 0.986 (0.672–
Diabetes (yes vs no) 1.330 (0.941–
Disease type
STEMI (vs UA or NSTEMI) 1.162 (0.824–
Other (vs UA or NSTEMI) 0.000 (0.000–
Study drug: prasugrel 20/3.75 mg (vs clopidogrel 300/75 mg) 0.997 (0.708–
HR, hazard ratio; CI, conﬁdence interval; eGFR, estimated glomerularﬁltration rate; STEMI, ST-e
infarction.
The multivariate model only included the variables sex, body weight, diabetes, and study drug
a Includes moderate and severe decreases in eGFR as well as end-stage renal failure.the study period revealed that being female or elderly, and having low
body weight or diabetes were predictors of these bleeding events
(Table 2). Complications of renal function, hypertension and drug use
were not associated with any of the above bleeding events.
4. Discussion
The PRASFIT-ACS study revealed that the incidence of MACE and
major, minor, and clinically relevant bleeding events were similar
between ACS patients treated with prasugrel or clopidogrel for
24–48weeks [2]. A post hoc analysis of the PRASFIT-ACS study revealed
that patients with a PRU N262 at 5–12 h after starting antiplatelet ther-
apy had a higher rate of MACE, with rates of 5.2% and 10.8% in patients
with PRU ≤262 or N262, respectively (odds ratio 0.50, 95% CI 0.25–0.99,
P b 0.01) [9]. Those results highlight the importance of maintaining
platelet reactivity below a threshold level to reduce the risk of MACE.
Other studies have also documented similar threshold values of PRU
for preventingMACE [13–22]. However, these earlier studies did not ad-
dress the other end of the therapeutic window by assessing a putative
relationship between low on-treatment platelet reactivity (i.e., high
platelet inhibition) and the risk of bleeding. Of note, in the post hoc
analyses reported here, we found no association between platelet reac-
tivity determined using the VerifyNow® assay or VASP assay and the
risk of bleeding, which was classiﬁed as major, minor, or clinically rele-
vant bleeding.
The Working Group on On-Treatment Platelet Reactivity recently
published an updated consensus on the deﬁnitions of on-treatment
platelet reactivity to adenosine diphosphate and the risk of ischemic
events and bleeding in an effort to improve the selection and manage-
ment of antiplatelet drugs in PCI [12]. The updated consensus proposed
new cutoffs for PRU (b85) and VASP-PRI (b16) for low on-treatment
platelet reactivity, and that PRU and VASP-PRI should be kept above
these values to reduce the risk of bleeding in clinical practice. Intriguing-
ly, when we deﬁned on-treatment platelet reactivity using these cutoff
values, we found that the risk of bleeding in these patients was similar
to that obtained using the other cutoff values (Table 1). These results
imply that the risk of bleeding is not increased in patients with low
on-treatment platelet reactivity. However, the number of patients
with low on-treatment platelet reactivity deﬁned using these cutoff
values was low, which may limit the reliability of this analysis.
The present results and the results of our previous analyses of the
PRASFIT-ACS study imply that there is an upper limit of platelet reactivity
for predicting MACE, but no lower limit for predicting bleeding events
occurring in the acute or chronic phase of treatment in Japanese ACS pa-
tients treated with prasugrel or clopidogrel after PCI.ciations of various background factorswith TIMImajor bleeding, TIMIminor bleeding, and
alysis Multivariate analysis
P value HR (95% CI) P value
3.534) b0.0001 1.667 (1.101–2.523) 0.0157
4.228) b0.0001 1.868 (1.156–3.020) 0.0107
3.128) b0.0001 1.715 (1.169–2.561) 0.0058
2.421) 0.0127
1.854) 0.8424
1.448) 0.9445
1.881) 0.1062 1.428 (1.001–2.036) 0.0493
1.638) 0.9779
∞) 0.9779
1.404) 0.9864 0.941 (0.666–1.328) 0.7274
levationmyocardial infarction; UA, unstable angina; NSTEMI, non-ST-elevationmyocardial
.
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example, Cuisset et al. assessed the relationship between very low
on-treatment platelet reactivity (VASP-PRI ≤ 10) and non-access
site-related bleeding complications deﬁned according to the Bleeding
Academic Research Consortium criteria [23]. The authors reported
that although treatment with prasugrel (vs. clopidogrel) was the stron-
gest predictor of low on-treatment platelet reactivity, low on-treatment
platelet reactivity was the strongest independent predictor of bleeding
(odds ratio 4.7; 95% CI 2.7–8.3; P b 0.001), opposite to the results of our
study.
There might be some explanations for the differences in results of
these studies. In particular, the lack of an association between low
PRU and bleeding may be due to the smaller number of patients with
low PRU in our study than in the study by Cuisset et al. [23]. It is also
possible that differences in the deﬁnitions of bleeding events or patient
characteristics contribute to the contrasting results of the two studies.
Furthermore, it is important to note that the studies used by theWorking
Group on On-Treatment Platelet Reactivity to propose cutoff values of
PRU and VASP-PRI were based in the US and Europe. It is possible that
the relative platelet reactivity may differ between Japanese and non-
Japanese patients [24].
Another aspect of our study that needs to bementioned is the fact that
weused a lower dose of prasugrel thanwas used in non-Japanese studies.
The dose used in our study was selected based on the results of Phase I
[25] and Phase II [26] studies, whereas the clopidogrel dose was the
same as that used in most non-Japanese studies, although some studies
also used higher doses of clopidogrel. These features of our study might
also contribute to the low incidence of bleeding and the low proportion
of patients with low on-treatment platelet reactivity.
It is also important to acknowledge that bleeding events occurring in
the acute phase tended to be associated with lower PRU and VASP-PRI
values in the prasugrel group than those in the clopidogrel group, but
events in the clopidogrel group were associated with higher PRU and
VASP-PRI values at 5–12 h after the loading dose (Figs. 2A and 3A,B).
This may reﬂect a quicker onset of antiplatelet activity in the prasugrel
group, particularly because of the PRU values were distributed towards
lower values in the prasugrel group than in the clopidogrel group at
5–12 h after the loading dose. Unfortunately, the small numbers of
events precluded meaningful statistical analyses to help understand
whether these differences are real.
Limitations of the study include its post hoc design and that the anal-
yseswere not stratiﬁed by treatment group. The latter, in particular, is of
interest considering the use of a lower prasugrel dose in the present
study than was used in prior studies. The relatively small sample size
might also contribute to the lack of an association between the pharma-
codynamics of prasugrel and clopidogrel and the incidence of bleeding
events in this study. We should also acknowledge the differences in
the numbers of patients with PRU and VASP-PRI values, particularly at
5–12 h after the LD. However, the assays were not mandatory and the
patient's clinical situation and limited resources at the necessary time
may have prevented staff from performing the assay(s).
Another factor that should be considered is that there were some
differences in the clinical characteristics of patients with PRU or
VASP-PRI data and patients without these data, particularly the timing
of the LD relative to PCI and other clinical factors/comorbidities
(Tables S5–S8). However, there were very few signiﬁcant differences
between the prasugrel and clopidogrel groups in patients without
PRU or VASP-PRI data. These data suggest that platelet reactivity was
not measured for reasons of time or patient's clinical status inﬂuenced
the clinician's decision on whether or not to measure PRU or VASP-PRI.
Finally, we used the TIMI criteria to assess bleeding events. These
criteria were introduced in the ﬁbrinolytic era and may not capture
the types of events that are likely to occur during PCI and antiplatelet
therapy [23]. Accordingly, it may be necessary to re-evaluate the present
results using more recent criteria, such as the Bleeding Academic Re-
search Consortium criteria [23].5. Conclusions
In conclusion, the analyses reported here revealed a lack of an asso-
ciation between the pharmacodynamics of prasugrel and clopidogrel
and the incidence of bleeding events in either the acute or chronic
phases of treatment following PCI in Japanese ACS patients. The results
of the PRASFIT-ACS study demonstrate the need for avoiding high on-
treatment platelet reactivity to reduce the risk of MACE, but low on-
treatment platelet reactivity does not appear to increase the risk of
bleeding events, at least in Japanese patients prescribed a low dose of
prasugrel or a standard dose of clopidogrel. These results also demon-
strate the wide therapeutic windows of prasugrel and clopidogrel, and
the low risk of major/minor/clinically relevant bleeding after PCI in
Japanese ACS patients.
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